Characterization of Biomarkers to Immune Checkpoint Inhibitor Therapy in Solid Tumors

被引：0
|
作者：
Huang, Xiu [1 ]
Russell, Meaghan K. [1 ]
Pantazi, Angeliki [2 ]
Lvova, Maria [1 ]
Vuzman, Dana [1 ]
Lyle, Stephen [3 ]
Tse, Julie Y. [4 ]
机构：
[1] KEW Inc, Cambridge, MA USA
[2] KEW Inc, Lethbridge, AB, Canada
[3] Univ Massachusetts, Worcester, MA 01605 USA
[4] KEW Inc, Tufts Med Ctr, Boston, MA USA
来源：
MODERN PATHOLOGY | 2018年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1950
引用
收藏
页码：701 / 701
页数：1
相关论文
共 50 条
  • [31] The inflammatory tumor microenvironment in patients with solid tumors with brain metastases after progression to immune checkpoint inhibitor therapy
    Starzer, A. M.
    Kleinberger, M.
    Feldmann, K.
    Tomasich, E.
    Hatziioannou, T.
    Paiato, C.
    Heller, G.
    Kreminger, J.
    Traint, S.
    Steindl, A.
    Ressler, J. M.
    Widhalm, G.
    Gatterbauer, B.
    Dieckmann, K.
    Muellauer, L.
    Preusser, M.
    Berghoff, A. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 272 - 272
  • [32] Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis
    Park, Hyo Jung
    Kim, Kyung Won
    Pyo, Junhee
    Suh, Chong Hyun
    Yoon, Shinkyo
    Hatabu, Hiroto
    Nishino, Mizuki
    RADIOLOGY, 2020, 297 (01) : 87 - 96
  • [33] Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy
    Parikh, Anish B.
    Zhong, Xiaobo
    Mellgard, George
    Qin, Qian
    Patel, Vaibhav G.
    Wang, Bo
    Alerasool, Parissa
    Garcia, Philip
    Leiter, Amanda
    Gallagher, Emily J.
    Clinton, Steven
    Mortazavi, Amir
    Monk, Paul
    Folefac, Edmund
    Yin, Ming
    Yang, Yuanquan
    Galsky, Matthew
    Oh, William K.
    Tsao, Che-Kai
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (03): : 114 - 120
  • [34] Biomarkers of immune checkpoint inhibitor efficacy in cancer
    Meyers, D. E.
    Banerji, S.
    CURRENT ONCOLOGY, 2020, 27 : S106 - S114
  • [35] Analysis of predictive biomarkers for immune checkpoint inhibitor therapy in several subtypes of sarcomas
    Xiao, Y.
    Zhang, H.
    Ma, X.
    Dong, S.
    Wang, L.
    Kang, J.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S986 - S987
  • [36] Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching
    Huerter, Mary M.
    Ganti, Apar Kishor
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S2195 - S2197
  • [37] Clinicians' perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumors.
    Moser, Kaitlynn
    Lindpaintner, Klaus
    Soto, Michelle
    Geba, Daniela
    Allen, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors
    Yang, Ximing
    Gao, Miaozhi
    Xu, Runshi
    Tao, Yangyang
    Luo, Wang
    Wang, Binya
    Zhong, Wenliang
    He, Lan
    He, Yingchun
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [39] Transcriptome-based assessment of immune infiltration for molecular selection of pediatric patients with solid tumors for combination immune checkpoint inhibitor therapy
    Shen, Yaoqing
    Mayoh, Chelsea
    Nabbi, Arash
    Santiago, Raoul
    Bianco, Stephanie
    Bancarz, Iain R.
    Williamson, Laura
    Corbett, Richard
    Krekhno, Zakhar
    Davidson, Scott
    Fortuna, Alexander
    Yuki, Kyoko E.
    Connolly, Denise
    Morgenstern, Daniel
    Ekert, Paul G.
    Shlien, Adam
    Jones, Steven J. M.
    Deyell, Rebecca J.
    Cohen-Gogo, Sarah
    CANCER RESEARCH, 2024, 84 (17)
  • [40] Effects of different immune microenvironment characteristics on predictive efficacy of PTCH1 mutations in immune checkpoint inhibitor therapy of solid tumors
    Zhu, Guangyu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345